Advicenne (ALDVI) - Total Liabilities
Based on the latest financial reports, Advicenne (ALDVI) has total liabilities worth €30.73 Million EUR (≈ $35.93 Million USD) as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Advicenne - Total Liabilities Trend (2014–2024)
This chart illustrates how Advicenne's total liabilities have evolved over time, based on quarterly financial data. See ALDVI working capital efficiency to evaluate short-term liquidity relative to the company's equity base.
Advicenne Competitors by Total Liabilities
The table below lists competitors of Advicenne ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Puncak Niaga Holdings Bhd
KLSE:6807
|
Malaysia | RM1.49 Billion |
|
Shinpoong Pharmaceutical Co Ltd
KO:019175
|
Korea | ₩79.62 Billion |
|
Tungray Technologies Inc Class A Ordinary Shares
NASDAQ:TRSG
|
USA | $9.08 Million |
|
CHARBONE HYDROGEN CORP.
F:K47
|
Germany | €10.91 Million |
|
FAWER Automotive Parts Ltd Co
SHE:200030
|
China | HK$9.40 Billion |
|
ReGen III Corp
V:GIII
|
Canada | CA$5.10 Million |
|
UMS Holdings Bhd
KLSE:7137
|
Malaysia | RM8.35 Million |
|
Quince Therapeutics, Inc.
NASDAQ:QNCX
|
USA | $10.95 Million |
Liability Composition Analysis (2014–2024)
This chart breaks down Advicenne's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see ALDVI market cap overview.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.59 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | 0.05 | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -1.28 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 4.57 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Advicenne's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Advicenne (2014–2024)
The table below shows the annual total liabilities of Advicenne from 2014 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | €28.58 Million ≈ $33.41 Million |
+17.24% |
| 2023-12-31 | €24.38 Million ≈ $28.50 Million |
-2.00% |
| 2022-12-31 | €24.88 Million ≈ $29.08 Million |
+33.94% |
| 2021-12-31 | €18.57 Million ≈ $21.71 Million |
-10.42% |
| 2020-12-31 | €20.73 Million ≈ $24.24 Million |
+245.80% |
| 2019-12-31 | €6.00 Million ≈ $7.01 Million |
+69.15% |
| 2018-12-31 | €3.54 Million ≈ $4.14 Million |
-30.59% |
| 2017-12-31 | €5.11 Million ≈ $5.97 Million |
-39.26% |
| 2016-12-31 | €8.41 Million ≈ $9.83 Million |
+80.80% |
| 2015-12-31 | €4.65 Million ≈ $5.44 Million |
+230.26% |
| 2014-12-31 | €1.41 Million ≈ $1.65 Million |
-- |
About Advicenne
Advicenne S.A., a specialty pharmaceutical company, develops, commercializes, and markets treatments for rare renal diseases in France and internationally. It offers Sibnayal for the treatment of metabolic disorders, distal renal tubular acidosis, and cystinuria. The company also distributes Likozam, a formulation of clobazam for the treatment of short-term symptomatic of severe, disabling, or co… Read more